Objectives: To review published data on the effectiveness of a progestogen-only pill
containing norgestrel 75 µg/day which should be under consideration by the FDA in 2022 for …

Over-the-counter oral contraceptives are an appropriate and important contraceptive option
for many adolescents. Over-the-counter availability has the potential to increase access to …

Objectives To develop a model to estimate the possible impact of use of an over-the-counter
(OTC) progestin-only pill (POP) on the number of unintended pregnancies in the United …

Objectives To estimate the availability of the recently released over-the-counter (OTC) birth
control pill (Opill) in retail pharmacies and compare availability across pharmacies based on …

In July 2023, the US Food and Drug Administration (FDA) approved the first over-the-counter
(OTC) daily oral contraceptive pill, Opill (nogestrel). This is the first daily oral contraceptive …

Abstract In July 2023, the US Food and Drug Administration approved Opill (norgestrel
0.075 mg), a progestin-only tablet to prevent pregnancy to be used without a prescription …

Objective: To assess whether evidence-based information on progestin-only pills (POPs)
and over-the-counter (OTC) oral contraceptives (OCs) increases support among clinicians …

Progestins are artificial derivatives of the naturally occurring steroid progesterone and
include most if not all, aspects of reproductive physiology and medicine. The functions of …

Public and private sector organizations have a role to play in advancing contraceptive
access and sexual and reproductive health equity (SRHE) more broadly. Private sector …

Abstract Changes in health insurance coverage, or insurance churn, is common in the
months surrounding pregnancy, but there has been limited study of how churn affects …